Exploratory biomarker analysis of ribociclib plus letrozole in recurrent low-grade serous carcinoma: A GOG-3026 correlative study.

OBJECTIVE: Ribociclib plus letrozole demonstrated meaningful activity in recurrent low-grade serous ovarian carcinoma (LGSOC) in the phase II GOG-3026 trial. However, biomarkers associated with CDK4/6 inhibitor response remain undefined. We conducted an exploratory translational analysis to identify molecular and immune biomarkers associated with clinical outcomes. METHODS: Archival FFPE tumors from 24 GOG-3026 patients were analyzed. Immunohistochemistry assessed ER, PR, p16, phosphorylated RB (pRB), and Ki-67. Whole-exome sequencing (n = 14) and RNA sequencing (n = 12) evaluated genomic alterations and immune transcriptional profiles. Associations between biomarkers and objective response rate (ORR), clinical benefit rate (CBR), progression-free survival (PFS) and overall survival were evaluated using 2-sided tests at a 5% significance level, without multiple testing adjustment. RESULTS: Among 24 patients, ORR was 37.5% and CBR was 87.5%. Lower Ki-67 expression was significantly associated with CBR (r = -0.437, p = 0.0326). Higher p16 expression showed a trend toward shorter PFS (Cox proportional hazard regression: HR 2.8, 95% CI 0.96-9.20; Monte Carlo permutation log-rank test: p = 0.0633). ER, PR, pRB expression and MAPK pathway alterations were not associated with response or survival. The most common genomic alterations involved BRAF, KRAS, NRAS and FANCD2. RNA sequencing identified three immune phenotypes: immune-hot, intermediate, and immune-cold. No partial responders had an immune-hot phenotype, while four of five partial responders clustered in the intermediate group. CONCLUSIONS: Lower Ki-67 expression may predict clinical benefit from ribociclib plus letrozole, while higher p16 expression may be associated with shorter PFS. Distinct immune phenotypes may also influence response, supporting prospective validation of proliferation-, cell-cycle-, and immune-based biomarkers to refine patient selection for CDK4/6-directed therapy in LGSOC.

Authors

Institutions

Publication Details

Journal
PubMed
Published
2026-11-13
DOI
https://doi.org/10.1016/j.ygyno.2026.11.003
Primary Topic
Ovarian cancer diagnosis and treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Exploratory biomarker analysis of ribociclib plus letrozole in recurrent low-grade serous carcinoma: A GOG-3026 correlative study.

Vivek Podder, David Marc Gershenson, Floor Backes, Thomas J. Herzog et al.
PubMed
Ovarian cancer diagnosis and treatment
article

Exploratory biomarker analysis of ribociclib plus letrozole in recurrent low-grade serous carcinoma: A GOG-3026 correlative study.

Vivek Podder, David Marc Gershenson, Floor Backes, Thomas J. Herzog, Yvonne T.M. Tsang, Hye Sook Chon, Meaghan Elizabeth Tenney, Eric Thomas, Merry Jennifer Markham, Kwong-kwok Wong, S John Weroha, Wei Deng, Shannon N Westin, Robert L Coleman, Brian M Slomovitz
article en

Abstract

OBJECTIVE: Ribociclib plus letrozole demonstrated meaningful activity in recurrent low-grade serous ovarian carcinoma (LGSOC) in the phase II GOG-3026 trial. However, biomarkers associated with CDK4/6 inhibitor response remain undefined. We conducted an exploratory translational analysis to identify molecular and immune biomarkers associated with clinical outcomes. METHODS: Archival FFPE tumors from 24 GOG-3026 patients were analyzed. Immunohistochemistry assessed ER, PR, p16, phosphorylated RB (pRB), and Ki-67. Whole-exome sequencing (n = 14) and RNA sequencing (n = 12) evaluated genomic alterations and immune transcriptional profiles. Associations between biomarkers and objective response rate (ORR), clinical benefit rate (CBR), progression-free survival (PFS) and overall survival were evaluated using 2-sided tests at a 5% significance level, without multiple testing adjustment. RESULTS: Among 24 patients, ORR was 37.5% and CBR was 87.5%. Lower Ki-67 expression was significantly associated with CBR (r = -0.437, p = 0.0326). Higher p16 expression showed a trend toward shorter PFS (Cox proportional hazard regression: HR 2.8, 95% CI 0.96-9.20; Monte Carlo permutation log-rank test: p = 0.0633). ER, PR, pRB expression and MAPK pathway alterations were not associated with response or survival. The most common genomic alterations involved BRAF, KRAS, NRAS and FANCD2. RNA sequencing identified three immune phenotypes: immune-hot, intermediate, and immune-cold. No partial responders had an immune-hot phenotype, while four of five partial responders clustered in the intermediate group. CONCLUSIONS: Lower Ki-67 expression may predict clinical benefit from ribociclib plus letrozole, while higher p16 expression may be associated with shorter PFS. Distinct immune phenotypes may also influence response, supporting prospective validation of proliferation-, cell-cycle-, and immune-based biomarkers to refine patient selection for CDK4/6-directed therapy in LGSOC.

PubMedVol. 215
Northside Hospital (US), Roswell Park Comprehensive Cancer Center (US), Mayo Clinic (US), The University of Texas MD Anderson Cancer Center (US), The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US), Moffitt Cancer Center (US), Mount Sinai Medical Center (US), Oklahoma Cancer Specialists and Research Institute (US), The US Oncology Network (US), University of Cincinnati (US)
Ovarian cancer diagnosis and treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon